# Predicting Recurrence in HR+/HER2- Early Breast Cancer

> **NCT07484763** · — · NOT_YET_RECRUITING · sponsor: **Shengjing Hospital** · enrollment: 500 (estimated)

## Conditions studied

- Breast Cancer, HR+/HER2- Early-Stage

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07484763
- **Lead sponsor:** Shengjing Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2026-07-01
- **Final completion:** 2027-04-01
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07484763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07484763, "Predicting Recurrence in HR+/HER2- Early Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07484763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*